熱門資訊> 正文

卡尔维斯塔（KalVista）获得英国认可埃克特利（Ekterly）

2025-07-16 04:44

KalVista Pharmaceuticals, Inc.(KALV) 0
優客工廠(UK) 0
纳比特(NA) 0

KalVista Pharmaceuticals (NASDAQ:KALV) said that the UK health regulator has granted marketing authorization for Ekterly (sebetralstat), a plasma inhibitor, to treat hereditary angioedema attacks in patients aged 12 years and older.
Ekterly's marketing authorization is based on phase 3 clinical trial results.

More on KalVista Pharmaceuticals

KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
KalVista Pharmaceuticals rises after FDA nod for Ekterly
FDA's Makary sought to reject KalVista’s drug: report
Seeking Alpha’s Quant Rating on KalVista Pharmaceuticals
Historical earnings data for KalVista Pharmaceuticals

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。